I 
1. 
BACKGROUND INFORMATION ON THE PROCEDURE
Submission of the dossier
The company Hoechst Marion Roussel Deutschland GmbH submitted on 6 February 1998 an
application for Marketing Authorisation to the European Agency for the Evaluation of Medicinal
Products (EMEA) for Arava, through the centralised procedure. The name of the Marketing
Authorisation Holder has been changed from Hoechst Marion Roussel Deutschland GmbH to Aventis
Pharma Deutschland GmbH (see steps after the Marketing Authorisation). After agreement by the
CPMP on 20 May 1999, this medicinal product has been referred to Part B of the Annex to Council
Regulation No (EEC) 2309/93 of 22 July 1993.
The Rapporteur and Co-Rapporteur appointed by the CPMP and the evaluation teams were:
Rapporteur: Dr Hans van Bronswijk
Co-Rapporteur:  Pharm. G. De Greef
Evaluators: Dr O. A. Lake (Quality)
Evaluators:
Dr. J. G. C. Van Amsterdam (Safety)
Dr F. van Zoest (Safety)
Dr. S. de Boer (Safety)
Dr H. W. Nab (Efficacy)
Dr P. Baede-van Dijk (Efficacy)
Prof. Y. Michotte (Quality)
Dr. P. Poukens-Renwart (Quality)
Dr W. Penninckx (Quality)
Dr M. Zeicher (Safety)
Dr A. Lhoir (Efficacy)
Licensing status:
The product was not licensed in any country at the time of submission of the application.
2. 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
Steps taken for the assessment of the product
The procedure started on 24 February 1998.
The  Rapporteur's  first  assessment  report  was  circulated  to  all  CPMP  Members  on
29 April 1998.
The  Co-Rapporteur’s  first  assessment  report  was  circulated  to  all  CPMP  Members  on
11 May 1998.
During the meeting on 23-25 June 1998 the CPMP agreed on the consolidated list of questions
to be sent to the applicant. The final consolidated list of questions was sent to the applicant on
25 June 1998.
The applicant submitted the responses to the consolidated list of questions on 4 December 1998.
The  Rapporteur/Co-Rapporteur  circulated  the  response  assessment  report  on  the  applicant’s
responses to the list of questions to all CPMP Members on 20 January 1999.
The applicant requested on 05 February 1999 a clock stop until the April 1999 CPMP meeting.
This request was agreed at the CPMP meeting on 25 February 1999.
List of outstanding issues was adopted at the CPMP meeting on 25 February 1999.
The applicant provided supplementary information on 22 March 1999.
During the meeting on 23-25 March 1999 the CPMP agreed that no inspection or sampling was
necessary.
The  applicant  gave  an  oral  presentation  on  20  April  1999  during  the  CPMP  meeting  and  the
remaining issues were presented.
A draft list of questions to be addressed by the applicant has been adopted at the CPMP meeting
on 22 April 1999 and the clock was stopped.
The applicant submitted the responses to the remaining list of questions along with a new SPC
and PIL on 04 May 1999.
CPMP/1694/99
1/2
EMEA 2000
• 
• 
• 
During the meeting on 18-20 May 1999 the CPMP, in the light of the overall data submitted and
the  scientific  discussion  within  the  committee,  issued  a  positive  opinion  by  majority  vote  for
granting a Marketing Authorisation to Arava on 20 May 1999.
During the CPMP meeting on 20 May 1999 a letter of undertaking has been adopted.
The  CPMP  Opinions  were  forwarded, in  all  official  languages  of  the  European  Union,  to  the
European Commission, which adopted the corresponding Decisions on 02 September 1999.
II.  GENERAL CONDITIONS FOR THE MARKETING AUTHORISATION
1. Manufacturing authorisation holder and inspection status
Manufacturer of the active substance
Aventis Pharma Deutschland GmbH
Industriepark Höchst
D-65926 Frankfurt/Main
Germany
Manufacturer of the finished medicinal product
Hoechst Marion Roussel-Usiphar
56 route de Choisy au Bac
F-60205 Compiègne
France
Manufacturer responsible for batch release in the European Economic Area
Aventis Pharma Deutschland GmbH
Industriepark Höchst
D-65926 Frankfurt/Main
Germany
The  Manufacturing  authorisation  was  issued  on  12  May  1998  by  Regierungspräsidium,  Darmstadt,
Germany.
2. 
Conditions or restrictions regarding supply and use
Medicinal product subject to restricted medical prescription (see section 4.2 of the SPC).
3. 
Follow Up measures of the marketing authorisation holder
The applicant agreed to provide additional information within the agreed timeframe as indicated in the
letter of undertaking (dated 29 April 1999).
CPMP/1694/99
2/2
EMEA 2000
